Please Wait...
LAVIXABAN is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Prophylaxis of deep vein thrombosis hip
or knee replacement surgery.
LAVIXABAN 5 is an anticoagulant medication that contains 5 mg of apixaban, designed to help prevent stroke and blood clots in patients with non-valvular atrial fibrillation.
It also treats and prevents deep vein thrombosis (DVT) and pulmonary embolism (PE). Apixaban works by selectively inhibiting Factor Xa, a crucial component in the blood clotting process.
The tablets are convenient to take, usually prescribed twice daily, with or without food. This formulation offers effective anticoagulation without the need for regular blood monitoring
Each film coated tablet contains:
Apixaban IH …………..5 mg
Excipients……………... Q.S
Oral
DOSAGE
As
directed by the physician.
• Increased risk of
Thrombotic events after premature discontinuation
• Bleeding
• Spinal/Epidural Anesthesia or Puncture
Premature discontinuation of any oral anticoagulant, including LAVIXABAN, in the absence of
adequate alternative anticoagulation
increases the risk of thrombotic events. An increased rate
of stroke was observed during the
transition from LAVIXABAN to warfarin in clinical trials in atrial
fibrillation patients. If LAVIXABAN is
discontinued for a reason other than pathological bleeding
6 x
10 Tablets